Hambrecht Cuts Noven Pharmaceuticals to 'Sell'

The FDA said says Noven's Methypatch for Hyperactivity is not approvable

WR Hambrecht downgraded Noven Pharmaceuticals (NOVN ) to sell.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.